Home/Pipeline
Program
PreclinicalPhase 1Phase 2Phase 3FiledApproved
Next milestoneCLV-501elvoparvecSpinal muscular atrophyRare Disease · Gene therapy
Long-term follow-up
CLV-508Duchenne muscular dystrophyRare Disease · Gene therapy
Pivotal cohort dosing
CLV-515Fabry diseaseRare Disease · RNA
First cohort dosed
CLV-522Rett syndromeRare Disease · Gene therapy
IND-enabling studies
Pipeline as of September 30, 2026. Programs and data are fictional.